According to the article published by NCBI, the projected 25% increase in NAFLD cases and 40% rise in NASH cases by 2030, along with an 85% rise in advanced liver disease and NAFLD-related deaths, underscores the growing burden of liver conditions in Australia. This escalating prevalence of liver diseases drives the demand for advanced surgeries, acting as a key driver for the HPB surgery market’s growth.In August 2023, according to WILEY Online LIbraray, the significant rise in NAFLD prevalence, from 32.7% to 38.8%, alongside the growing rates of obesity and unhealthy diets, particularly among women, highlights the increasing burden of liver diseases in Australia. As NAFLD progresses, many patients require additional tests for fibrosis, driving the demand for specialized treatments and surgeries. This trend acts as a major driver for the HPB surgery market The growing incidence of liver and pancreatic diseases, such as liver cirrhosis, pancreatitis, and pancreatic cancer, is significantly driving the Australian HPB surgery market. As these conditions become more common due to factors like unhealthy lifestyles, aging populations, and rising alcohol consumption, the demand for advanced surgical procedures like liver transplants, pancreatic resections, and biliary surgeries increases. This surge in disease prevalence is pushing the healthcare sector to focus on specialized surgical treatments and innovative solutions. The expanding need for such services is fueling growth in the HPB surgery market, acting as a major market driver.
